Inhibition of p38 mitogen-activated protein kinase protects the heart against cardiac remodeling in mice with heart failure resulting from myocardial infarction

Journal of Cardiac Failure

Volumn 11, Issue 1, 2005, Pages 74-81

  Liu, Yun He ^a   Wang, Dahai ^a   Rhaleb, Nour Eddine ^a   Yang, Xiao Ping ^a   Xu, Jiang ^a   Sankey, Steadman S ^b   Rudolph, Amy E ^c   Carretero, Oscar A ^a  

^a HENRY FORD HOSPITAL   (United States)

^b Div Biostatist and Res Epidemiol

^c PFIZER INC   (United States)

Author keywords

ACEi; Cardiac function; HF; p38 MAPK inhibitors; Remodeling

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; MITOGEN ACTIVATED PROTEIN KINASE P38; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; SC 409; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY LIGATION; DIASTOLE; ECHOCARDIOGRAPHY; ENZYME INHIBITION; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE CELL; HEART OUTPUT; HEART PROTECTION; HISTOPATHOLOGY; LEFT ANTERIOR DESCENDING CORONARY ARTERY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE;

EID: 13444256258     PISSN: 10719164     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cardfail.2004.04.004     Document Type: Article

References (43)

1. Adams J.W., Sakata Y., Davis M.G., Sah V.P., Wang Y., Liggett S.B., et al. Enhanced Gαq signaling: a common pathway mediates cardiac hypertrophy and apoptotic heart failure. Proc Natl Acad Sci U S A. 95:1998;10140-10145
2. Clerk A., Sugden P.H. Activation of protein kinase cascades in the heart by hypertrophic G protein-coupled receptor agonists. Am J Cardiol. 83:1999;64H-69H
3. Wang Y., Huang S., Sah V.P., Ross J. Jr., Brown J.H., Han J., et al. Cardiac muscle cell hypertrophy and apoptosis induced by distinct members of the p38 mitogen-activated protein kinase family. J Biol Chem. 273:1998;2161-2168
4. Hayashida W., Kihara Y., Yasaka A., Inagaki K., Iwanaga Y., Sasayama S. Stage-specific differential activation of mitogen-activated protein kinases in hypertrophied and failing rat hearts. J Mol Cell Cardiol. 33:2001;733-744
5. Barancik M., Htun P., Strohm C., Kilian S., Schaper W. Inhibition of the cardiac p38-MAPK pathway by SB203580 delays ischemic cell death. J Cardiovasc Pharmacol. 35:2000;474-483
6. Haq S., Choukroun G., Lim H., Tymitz K.M., del Monte F., Gwathmey J., et al. Differential activation of signal transduction pathways in human hearts with hypertrophy versus advanced heart failure. Circulation. 103:2001;670-677
7. Cook S.A., Sugden P.H., Clerk A. Activation of c-Jun N-terminal kinases and p38-mitogen-activated protein kinases in human heart failure secondary to ischaemic heart disease. J Mol Cell Cardiol. 31:1999;1429-1434
8. Sugden P.H., Clerk A. "Stress-responsive" mitogen-activated protein kinases (c-Jun N-terminal kinases and p38 mitogen-activated protein kinases) in the myocardium. Circ Res. 83:1998;345-352
9. Ma X.L., Kumar S., Gao F., Louden C.S., Lopez B.L., Christopher T.A., et al. Inhibition of p38 mitogen-activated protein kinase decreases cardiomyocyte apoptosis and improves cardiac function after myocardial ischemia and reperfusion. Circulation. 99:1999;1685-1691
10. Wenzel S., Taimor G., Piper H.M., Schlüter K.-D. Redox-sensitive intermediates mediate angiotensin II-induced p38 MAP kinase activation, AP-1 binding activity, and TGF-β expression in adult ventricular cardiomyocytes. FASEB J. 15:2001;2291-2293
11. Liao P., Georgakopoulos D., Kovacs A., Zheng M., Lerner D., Pu H., et al. The in vivo role of p38 MAP kinases in cardiac remodeling and restrictive cardiomyopathy. Proc Natl Acad Sci U S A. 98:2001;12283-12288
12. Liao P., Wang S.-Q., Wang S., Zheng M., Zheng M., Zhang S.-J., et al. p38 mitogen-activated protein kinase mediates a negative inotropic effect in cardiac myocytes. Circ Res. 90:2002;190-196
13. Behr T.M., Nerurkar S.S., Nelson A.H., Coatney R.W., Woods T.N., Sulpizio A., et al. Hypertensive end-organ damage and premature mortality are p38 mitogen-activated protein kinase-dependent in a rat model of cardiac hypertrophy and dysfunction. Circulation. 104:2001;1292-1298
14. Sander G.E., McKinnie J.J., Greenberg S.S., Giles T.D. Angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists in the treatment of heart failure caused by left ventricular systolic dysfunction. Prog Cardiovasc Dis. 41:1999;265-300
15. Touyz R.M., He G., El Mabrouk M., Schiffrin E.L. p38 MAP kinase regulates vascular smooth muscle cell collagen synthesis by angiotensin II in SHR but not in WKY. Hypertension. 37:2001;574-580
16. Pellieux C., Sauthier T., Aubert J.-F., Brunner H.-R., Pedrazzini T. Angiotensin II-induced cardiac hypertrophy is associated with different mitogen-activated protein kinase activation in normotensive and hypertensive mice. J Hypertens. 18:2000;1307-1317
17. van Eickels M., Grohe C., Lobbert K., Stimpel M., Vetter H. Angiotensin converting enzyme inhibitors block mitogenic signalling pathways in rat cardiac fibroblasts. Naunyn Schmiedebergs Arch Pharmacol. 359:1999;394-399
18. Yang F., Liu Y.-H., Yang X.-P., Xu J., Kapke A., Carretero O.A. Myocardial infarction and cardiac remodelling in mice. Exp Physiol. 87:2002;547-555
19. Krege J.H., Hodgin J.B., Hagaman J.R., Smithies O. A noninvasive computerized tail-cuff system for measuring blood pressure in mice. Hypertension. 25:1995;1111-1115
20. Yang X.-P., Liu Y.-H., Rhaleb N.-E., Kurihara N., Kim H.E., Carretero O.A. Echocardiographic assessment of cardiac function in conscious and anesthetized mice. Am J Physiol. 277:1999;H1967-H1974
21. Liu Y.-H., Yang X.-P., Nass O., Sabbah H.N., Peterson E., Carretero O.A. Chronic heart failure induced by coronary artery ligation in Lewis inbred rats. Am J Physiol. 272:1997;H722-H727
22. Liu Y.-H., Yang X.-P., Sharov V.G., Nass O., Sabbah H.N., Peterson E., et al. Effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists in rats with heart failure: role of kinins and angiotensin II type 2 receptors. J Clin Invest. 99:1997;1926-1935
23. Yu J.J., Tripp C.S., Russell J.H. Regulation and phenotype of an innate Th1 cell: role of cytokines and the p38 kinase pathway. J Immunol. 171:2003;6112-6118
24. Schindler J.F., Godbey A., Hood W.F., Bolten S.L., Broadus R.M., Kasten T.P., et al. Examination of the kinetic mechanism of mitogen-activated protein kinase activated protein kinase-2. Biochim Biophys Acta. 1598:2002;88-97
25. Lee J.C., Laydon J.T., McDonnell P.C., Gallagher T.F., Kumar S., Green D., et al. A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature. 372:1994;739-746
26. Stein B., Brady H., Yang M.X., Young D.B., Barbosa M.S. Cloning and characterization of MEK6, a novel member of the mitogen-activated protein kinase kinase cascade. J Biol Chem. 271:1996;11427-11433
27. Michel M.C., Li Y., Heusch G. Mitogen-activated protein kinases in the heart. Naunyn Schmiedebergs Arch Pharmacol. 363:2001;245-266
28. Sugden P.H. Signaling in myocardial hypertrophy. Life after calcineurin? Circ Res. 84:1999;633-646
29. Izumi Y., Kim S., Murakami T., Yamanaka S., Iwao H. Cardiac mitogen-activated protein kinase activities are chronically increased in stroke-prone hypertensive rats. Hypertension. 31:1998;50-56
30. Xia Z., Dickens M., Raingeaud J., Davis R.J., Greenberg M.E. Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science. 270:1995;1326-1331
31. Ono K., Han J. The p38 signal transduction pathway. Activation and function. Cell Signal. 12:2000;1-13
32. Hefti M.A., Harder B.A., Eppenberger H.M., Schaub M.C. Signaling pathways in cardiac myocyte hypertrophy. J Mol Cell Cardiol. 29:1997;2873-2892
33. Obata T., Brown G.E., Yaffe M.B. MAP kinase pathways activated by stress: the p38 MAPK pathway. Crit Care Med. 28:(Suppl.):2000;N67-N77
34. Chien K.R. Stress pathways and heart failure. Cell. 98:1999;555-558
35. Anversa P. Myocyte apoptosis and heart failure. Eur Heart J. 19:1998;359-360
36. Galán A., García-Bermejo M.L., Troyano A., Vilaboa N.E., de Blas E., Kazanietz M.G., et al. Stimulation of p38 mitogen-activated protein kinase is an early regulatory event for the cadmium-induced apoptosis in human promonocytic cells. J Biol Chem. 275:2000;11418-11424
37. Ichijo H., Nishida E., Irie K., ten Dijke P., Saitoh M., Moriguchi T., et al. Induction of apoptosis by ASK1, a mammalian MAPKKK that activates SAPK/JNK and p38 signaling pathways. Science. 275:1997;90-94
38. Bryant D., Becker L., Richardson J., Shelton J., Franco F., Peshock R., et al. Cardiac failure in transgenic mice with myocardial expression of tumor necrosis factor-α Circulation. 97:1998;1375-1381
39. Franco F., Thomas G.D., Giroir B., Bryant D., Bullock M.C., Chwialkowski M.C., et al. Magnetic resonance imaging and invasive evaluation of development of heart failure in transgenic mice with myocardial expression of tumor necrosis factor-α Circulation. 99:1999;448-454
40. Mann D.L. Inflammatory mediators and the failing heart. Past, present, and the foreseeable future. Circ Res. 91:2002;988-998
41. Pfeffer M.A., Braunwald E., Moyé L.A., Basta L., Brown E.J. Jr., Cuddy T.E., et al., on behalf of the SAVE Investigators. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the Survival and Ventricular Enlargement trial. N Engl J Med. 327:1992;669-677
42. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 316:1987;1429-1435
43. Liu Y.-H., Yang X.-P., Mehta D., Bulagannawar M., Scicli G.M., Carretero O.A. Role of kinins in chronic heart failure and in the therapeutic effect of ACE inhibitors in kininogen-deficient rats. Am J Physiol Heart Circ Physiol. 278:2000;H507-H514